NCT05415501 is a NA clinical trial of Sentence training in Aphasia, sponsored by Purdue University.

Who is sponsoring NCT05415501?

NCT05415501 is sponsored by Purdue University.

What drugs are being tested in NCT05415501?

Interventions in NCT05415501: Sentence training.

Is NCT05415501 still recruiting?

NCT05415501 is currently recruiting now. Last updated 18 December 2024.

Last reviewed 2024-12-18 · How we verify

NCT05415501

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sentence Production Training in Aphasia

Recruiting now NA Last updated 18 December 2024

What this trial tests

NA trial testing Sentence training in Aphasia in 104 participants. Currently enrolling.

Timeline

1 August 2021

Primary endpoint
30 May 2026

30 May 2026

Quick facts

Lead sponsor	Purdue University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	104
Start date	1 August 2021
Primary completion	30 May 2026
Estimated completion	30 May 2026
Sites	1 location across United States

Drugs / interventions tested

Sentence training

Conditions studied

Aphasia — all drugs for Aphasia →

Sponsor

Purdue University

Who can join

Adults 21 to 85, any sex, with Aphasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project focuses on developing a novel treatment for sentence production and comprehension in aphasia, using implicit priming. First set of experiments will aim examine which learning conditions are most effective in creating maximal training gains. Then, in a later study, the investigators will develop and test the efficacy of a novel treatment study based on findings from the first set of the studies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Implicit structural priming as a treatment component for aphasia: Specifying essential learning conditions.
Lee J, van Boxtel WS, Weirick JD, Ferreira V, et al · · 2024 · cited 3× · PMID 40179208 · DOI 10.1080/02643294.2025.2479485
Structural Priming Treatment in Aphasia: The Role of Lexical and Abstract Syntactic Representations.
van Boxtel WS, Rainey KM, Ferreira V, Martin N, et al · · 2025 · PMID 41124315 · DOI 10.1044/2025_ajslp-25-00095

Verify or expand the search:

Other recruiting trials for Aphasia

Currently open trials in the same condition.

NCT07460037 — Chinese-Specific Speech Imagery Coding Using High-Density ECoG · NA · recruiting
NCT07397923 — Exploratory Evaluation of the Digital Therapeutic Device Zenicom for Subacute Stroke Aphasia · Phase 2 · recruiting
NCT07281313 — Aphasia Physical EXercise Study: Randomized Trial · NA · recruiting
NCT06990997 — Effects of Aphasia Identification Cards on Service Workers' Comprehension of People With Aphasia · NA · recruiting
NCT06974279 — Post-Stroke Aphasia TMS · NA · recruiting

Other Purdue University trials

Trials by the same sponsor.

NCT07287774 — Evaluating a Deep Neural Noise-Reduction Algorithm for Hearing Aids · NA · recruiting
NCT07086833 — The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities · NA · recruiting
NCT06638944 — Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease · Phase 2 · recruiting
NCT07048392 — Retrieval-Based Word Learning in Developmental Language Disorder During Book Reading II · NA · recruiting
NCT06258941 — Classroom Break, Cognition, and Fitness in Elementary School Children · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05415501 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Purdue University
Last refreshed: 18 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05415501.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing